Menorrhagia is a common problem among women. The pathophysiology has been attributed to Von Willebrand’s disease in some patients. The lab diagnosis and confirmation of this condition in these women is often difficult. The need for easily reproducible, validated lab investigations is recognized. The platelet function analyzer (PFA-100) (described below) has recently been used as an adjunct for lab diagnosis of this condition. Use of this device is relatively recent, thus clinical correlation with its results have been lacking. Therefore, we initiated a study to determine if a correlation could be established between pictorial blood assessment chart (PBAC), PFA-100, and Von Willebrand’s screening (VWF antigen and co-factor activity levels).

Materials and methods: After obtaining informed consent 15 female patients with a diagnosis of von Villebrand’s disease were enrolled in the above study. All received verbal and written instructions of how to record their tampon/pad use on the PBAC. The PBAC was then scored on a validated and well-established point system for lightly (1point), moderately (2points) and heavily (3points) soiled pads or tampons. In addition their blood samples were analyzed for von Willebrand antigen, Ristocetin Co-Factor and on the PFA-100 (pre and post DDAVP). The PFA-100, is a high shear-inducing device which simulates primary hemostasis after injury to small vessel, which consists of a reservoir for whole blood and a small capillary surmounted by a collagen-coated membrane with a central aperture. Platelet agonist which is either epinephrine or ADP is present on the membrane. Closure time is reported as a variable which describes von Willebrand factor function. All blood samples were forwarded to Children’s Hospital of Buffalo Special Coagulation lab for examination of the PFA-100(pre and post DDAVP),and von Willebrand panel.

Conclusion: There was correlation between the number of points self-assessed on the PBAC and the PFA-100.

Summary Data

Patient #Age# points/PBACVWFRistocetin Co FactorFactor VIIIPFA 100 Pre DDAVP
48 10 56 52 70 104 
47 23 73 53 138 90 
21 69 70 63 151 
47 180 75 51 120 280 
44 25 107 68 114 124 
49 47 102 93 74 63 
25 12 74 51 84 177 
26 30 28 77 216 
30 24 47 64 115 125 
10 27 11 76 45 60 118 
11 25 10 66 49 79 136 
12 48 11 51 48 121 117 
13 25 59 42 44 99 
14 23 41 33 11 34 275 
15 46 84 11 300 
Patient #Age# points/PBACVWFRistocetin Co FactorFactor VIIIPFA 100 Pre DDAVP
48 10 56 52 70 104 
47 23 73 53 138 90 
21 69 70 63 151 
47 180 75 51 120 280 
44 25 107 68 114 124 
49 47 102 93 74 63 
25 12 74 51 84 177 
26 30 28 77 216 
30 24 47 64 115 125 
10 27 11 76 45 60 118 
11 25 10 66 49 79 136 
12 48 11 51 48 121 117 
13 25 59 42 44 99 
14 23 41 33 11 34 275 
15 46 84 11 300 

Author notes

Corresponding author

Sign in via your Institution